Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Healthcare | Biotechnology | Netherlands
statements
Index- P/E- EPS (ttm)-3.12 Insider Own1.10% Shs Outstand44.39M Perf Week19.21%
Market Cap1.83B Forward P/E- EPS next Y-1.79 Insider Trans-13.47% Shs Float42.13M Perf Month14.72%
Income-135.60M PEG- EPS next Q1.81 Inst Own95.20% Short Float9.50% Perf Quarter3.98%
Sales5.30M P/S346.03 EPS this Y-32.80% Inst Trans1.06% Short Ratio9.61 Perf Half Y-33.45%
Book/sh5.98 P/B7.13 EPS next Y-378.30% ROA-31.50% Target Price74.00 Perf Year-7.37%
Cash/sh7.31 P/C5.84 EPS next 5Y- ROE-44.00% 52W Range34.38 - 76.69 Perf YTD-40.51%
Dividend- P/FCF- EPS past 5Y-1.30% ROI-33.70% 52W High-44.41% Beta1.31
Dividend %- Quick Ratio10.70 Sales past 5Y3.50% Gross Margin- 52W Low24.00% ATR1.84
Employees248 Current Ratio10.70 Sales Q/Q-40.00% Oper. Margin- RSI (14)68.16 Volatility5.15% 4.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-15.50% Profit Margin- Rel Volume1.33 Prev Close41.26
ShortableYes LT Debt/Eq0.13 Earnings- Payout- Avg Volume416.43K Price42.63
Recom1.80 SMA2014.66% SMA5010.26% SMA200-15.95% Volume552,592 Change3.32%
Oct-23-20Initiated RBC Capital Mkts Outperform $61
Aug-25-20Initiated Raymond James Strong Buy $75
Jul-31-20Upgrade Robert W. Baird Neutral → Outperform $57
Jun-25-20Downgrade Wells Fargo Overweight → Equal Weight $56
Jun-25-20Downgrade Robert W. Baird Outperform → Neutral $58
Jun-25-20Downgrade Mizuho Buy → Neutral $90 → $61
Dec-03-19Initiated Goldman Buy
Dec-03-19Initiated Cowen Outperform
Nov-05-19Initiated Credit Suisse Outperform
Oct-11-19Initiated Stifel Buy
Sep-25-19Initiated Bernstein Outperform $73
Sep-12-19Initiated Mizuho Buy
Jul-30-19Downgrade Guggenheim Buy → Neutral
Jul-08-19Reiterated Cantor Fitzgerald Overweight $81 → $94
Apr-12-19Initiated Piper Jaffray Overweight $80
Mar-29-19Initiated Robert W. Baird Outperform $85
Mar-04-19Reiterated Chardan Capital Markets Buy $70 → $100
Feb-25-19Reiterated Cantor Fitzgerald Overweight $68 → $81
Feb-11-19Reiterated H.C. Wainwright Buy $60 → $73
Dec-31-18Resumed B. Riley FBR Buy $72
Oct-19-20 12:31PM  
UniQure (QURE) to Report Q3 Results: Wall Street Expects Earnings Growth
Zacks
Oct-13-20 07:05AM  
uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingtons Disease
GlobeNewswire
Sep-30-20 07:05AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in October
GlobeNewswire
Sep-25-20 07:05AM  
uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingtons Disease
GlobeNewswire
Sep-23-20 10:28AM  
3 Strong Buy Stocks That Are Flirting With a Bottom
TipRanks -5.19%
Sep-15-20 09:06AM  
Loss-Making uniQure N.V. (NASDAQ:QURE) Set To Breakeven
Simply Wall St. -5.10%
Sep-03-20 07:05AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in September
GlobeNewswire
Aug-31-20 10:21PM  
Hedge Funds Cant Buy Enough Of Uniqure NV (QURE)
Insider Monkey
08:56AM  
Implied Volatility Surging for uniQure (QURE) Stock Options
Zacks
Aug-26-20 10:44PM  
5 Biotech Stocks That Could Be Worth a Look
Barrons.com
07:05AM  
uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
GlobeNewswire
Jul-30-20 10:25AM  
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
Zacks
07:05AM  
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
GlobeNewswire
Jul-27-20 12:31PM  
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks
Jul-08-20 12:38PM  
Were Hedge Funds Right About Piling Into Uniqure NV (QURE)?
Insider Monkey
Jun-25-20 08:26AM  
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
Benzinga -21.76%
07:54AM  
UniQure's shares fall on licensing deal for gene therapy
MarketWatch
Jun-24-20 06:28PM  
CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
PR Newswire -7.13%
04:05PM  
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
GlobeNewswire
Jun-19-20 07:05AM  
uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingtons Disease
GlobeNewswire
Jun-17-20 04:05PM  
uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
GlobeNewswire
Jun-15-20 07:05AM  
uniQure Announces Change for its 2020 Annual General Meeting of Shareholders
GlobeNewswire
Jun-01-20 09:29AM  
Moving Average Crossover Alert: uniQure
Zacks
May-29-20 07:38PM  
Hedge Funds Done Buying Uniqure NV (QURE)?
Insider Monkey +6.57%
May-18-20 07:49AM  
Analysts Have Just Cut Their uniQure N.V. (NASDAQ:QURE) Revenue Estimates By 16%
Simply Wall St.
May-14-20 07:00AM  
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
GlobeNewswire
May-11-20 11:13PM  
JPMorgan Genetic-Therapies Fund Finds Success in Covid-19 Era
Bloomberg
Apr-29-20 08:45AM  
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Zacks
07:00AM  
uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
GlobeNewswire
Apr-28-20 04:51PM  
uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting
GlobeNewswire
Apr-27-20 12:32PM  
Earnings Preview: uniQure (QURE) Q1 Earnings Expected to Decline
Zacks
Apr-24-20 04:21PM  
Why Sanofi CEO's Comments Lit A Fire Under Gene Therapy Stocks
Investor's Business Daily +9.03%
Apr-21-20 10:47AM  
Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Simply Wall St.
Apr-17-20 07:00AM  
uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors
GlobeNewswire
Mar-30-20 07:00AM  
uniQure to Participate in Multiple Upcoming Investor Conferences in April
GlobeNewswire
Mar-28-20 09:10PM  
Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
Insider Monkey
Mar-26-20 12:36PM  
Biotech delays U.S. gene therapy launch due to outbreak, FDA discord
American City Business Journals
07:00AM  
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
GlobeNewswire
Mar-18-20 06:01AM  
Biotech pushes blood disorder cell therapy to clinic after $80M round
American City Business Journals
Mar-03-20 07:00AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in March
GlobeNewswire
Mar-02-20 05:45PM  
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Zacks +5.65%
04:05PM  
uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
GlobeNewswire
04:05PM  
uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
GlobeNewswire
Feb-27-20 07:00AM  
uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDIs 15th Annual Huntingtons Disease Therapeutics Conference
GlobeNewswire
Feb-26-20 08:41AM  
Why Earnings Season Could Be Great for uniQure (QURE)
Zacks
Feb-21-20 10:48AM  
Before You Buy uniQure N.V. (NASDAQ:QURE), Consider Its Volatility
Simply Wall St.
Feb-20-20 12:31PM  
UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks
Feb-04-20 07:00AM  
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
GlobeNewswire
Jan-31-20 07:00AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in February
GlobeNewswire
Jan-10-20 02:20PM  
Cambridge startup raises $110M for re-doseable gene therapies
American City Business Journals
Jan-07-20 12:12PM  
uniQure (NASDAQ:QURE) Shareholders Have Enjoyed A Magnificent 1077% Share Price Gain
Simply Wall St.
Dec-24-19 09:30AM  
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A
Zacks
Dec-19-19 10:27AM  
One particular field of drug development could dominate M&A in 2020
American City Business Journals
07:00AM  
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntingtons Disease Supporting Non-Selective HTT-Lowering Approach
GlobeNewswire
Dec-17-19 09:11AM  
5 Biotech Stocks That Have More Than Doubled This Year
Zacks
07:02AM  
Will uniQure Continue to Surge Higher?
Zacks
06:00AM  
Atlas, MPM, Partners funnel $49M into a new gene-silencing startup
American City Business Journals
Dec-16-19 09:34AM  
5 Biotech Stocks Set for Continued Rally in 2020
Zacks
Dec-08-19 04:00PM  
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
GlobeNewswire
Dec-06-19 09:33AM  
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
Zacks
Dec-05-19 04:32PM  
Astellas-Audentes Deal Likely to Ignite More Acquisitions
GuruFocus.com
10:12AM  
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
Zacks
03:49AM  
Gene Therapy the Next Best Thing: Here's Why (Revised)
Zacks
Dec-04-19 09:42AM  
Gene Therapy the Next Best Thing: Here's Why
Zacks
Dec-03-19 11:53AM  
The Gene Therapy Names Moving On The Audentes Buyout Deal
Benzinga +16.68%
Dec-02-19 07:00AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in December
GlobeNewswire
Nov-30-19 07:02PM  
Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
Insider Monkey
Nov-22-19 10:16AM  
Investors Hope for More From Takeda Than a Healthy Dividend
GuruFocus.com
Nov-07-19 09:45AM  
uniQure N.V. (QURE) Shares March Higher, Can It Continue?
Zacks
Nov-06-19 09:16AM  
uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
GlobeNewswire
Nov-05-19 07:00AM  
uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy
GlobeNewswire
Nov-01-19 07:00AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in November
GlobeNewswire
Oct-31-19 07:00AM  
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
GlobeNewswire
Oct-30-19 11:46AM  
Are Insiders Selling uniQure N.V. (NASDAQ:QURE) Stock?
Simply Wall St.
10:38AM  
uniQure N.V. (QURE) Shares March Higher, Can It Continue?
Zacks
Oct-29-19 12:37PM  
Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
Insider Monkey
Oct-28-19 08:15AM  
UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
Zacks
07:00AM  
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
GlobeNewswire
Oct-25-19 09:15AM  
S&P, NASDAQ Up Again in Mixed Session
Zacks +7.41%
Oct-02-19 09:33AM  
Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO
American City Business Journals
Oct-01-19 01:43PM  
Biotech Roundtable: How to Invest in Medicines Future
Barrons.com -5.67%
Sep-30-19 11:10AM  
Is uniQure N.V.'s (NASDAQ:QURE) CEO Pay Justified?
Simply Wall St.
Sep-27-19 07:00AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in October
GlobeNewswire
Sep-26-19 10:34AM  
Hedge Fund P.A.W. Capital Partners Top Stock Picks
Insider Monkey -6.36%
Sep-05-19 08:39PM  
uniQure Announces Pricing of its Public Offering
GlobeNewswire -14.86%
08:12AM  
The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
Benzinga
Sep-04-19 04:02PM  
uniQure Announces Proposed Public Offering
GlobeNewswire
Sep-03-19 07:00AM  
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
GlobeNewswire
Aug-30-19 08:32AM  
uniQure (NASDAQ:QURE) Has Debt But No Earnings; Should You Worry?
Simply Wall St.
07:00AM  
uniQure to Participate in Multiple Upcoming Industry Conferences in September
GlobeNewswire
Aug-20-19 07:00AM  
uniQure Announces Leadership Promotions and Executive Transition
GlobeNewswire
Aug-16-19 06:20AM  
Gene therapies to test FDA's approach to regulating drugs after launch, experts say
American City Business Journals
Jul-31-19 06:28AM  
Introducing uniQure (NASDAQ:QURE), The Stock That Soared 653% In The Last Three Years
Simply Wall St.
Jul-29-19 08:35AM  
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
Zacks -5.38%
07:18AM  
uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress
GlobeNewswire
Jul-26-19 07:00AM  
uniQure to Participate in Multiple Upcoming Industry Conferences
GlobeNewswire
Jul-19-19 12:15PM  
Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of Shares
GuruFocus.com
Jul-11-19 05:33AM  
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
Zacks
Jul-09-19 11:07AM  
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study
Zacks
Jul-08-19 08:19AM  
What Drove uniQure 171% Higher in the First Half of 2019
Motley Fool
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, CFO, Managing DirectorOct 14Sale35.865,250188,256280,564Oct 16 04:10 PM
Gut RobertChief Medical OfficerSep 21Sale39.124,352170,25041,523Sep 22 09:48 AM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 18Sale41.182,23091,83156,860Sep 22 09:54 AM
Kapusta Matthew CCEO, CFO, Managing DirectorSep 16Sale40.667,500304,939285,814Sep 18 01:41 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 25Sale40.2730012,081293,314Aug 27 05:00 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 19Sale39.114,300168,175293,614Aug 21 04:32 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJul 22Sale42.315,626238,025297,914Jul 24 04:41 PM
Gut RobertChief Medical OfficerJun 23Option Exercise39.1226,8751,051,34472,750Jun 24 04:21 PM
Gut RobertChief Medical OfficerJun 23Sale70.0026,8751,881,25045,875Jun 24 04:21 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 17Sale66.047,501495,366303,540Jun 22 04:43 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMay 20Sale59.947,501449,580311,041May 22 05:13 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Option Exercise26.412,25059,42359,268Apr 28 04:29 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Sale60.002,250135,00057,018Apr 28 04:29 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Option Exercise7.539,37670,601327,918Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Sale56.879,376533,205318,542Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Option Exercise7.535,62642,364324,168Mar 20 01:16 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Sale41.485,626233,352318,542Mar 20 01:16 PM
KLEMT CHRISTIANChief Accounting OfficerMar 04Option Exercise26.4115,750415,95872,768Mar 06 10:07 AM
KLEMT CHRISTIANChief Accounting OfficerMar 04Sale52.2915,750823,50057,018Mar 06 10:07 AM
Kapusta Matthew CCEO, CFO, Managing DirectorFeb 19Sale64.567,501484,256284,753Feb 21 10:03 AM
Soteropoulos PaulaDirectorFeb 05Sale60.952,122129,3322,423Feb 05 01:19 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 31Sale57.983,872224,499264,541Jan 31 03:45 PM
Astley-Sparke PhilipDirectorJan 30Sale59.2380747,7996,005Jan 30 09:39 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 30Sale59.3123,5831,398,646268,413Jan 31 03:45 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 29Sale61.9423,5831,460,794291,996Jan 31 03:45 PM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 28Sale62.141,47891,84840,100Jan 30 09:36 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale61.9223,5831,460,221315,579Jan 29 11:24 AM
Kaye JackDirectorJan 28Sale62.2080650,13314,128Jan 30 09:32 PM
Balachandran MadhavanDirectorJan 28Sale62.2080750,1956,005Jan 30 09:23 PM
Soteropoulos PaulaDirectorJan 28Sale62.1980750,1874,545Jan 30 09:15 PM
van Deventer SanderEVP, Research & Product Dev.Jan 28Sale61.612,227137,21443,127Jan 30 09:11 PM
SCHAFFER DAVIDDirectorJan 28Sale62.2780650,19044,915Jan 30 09:06 PM
KLEMT CHRISTIANChief Accounting OfficerJan 28Sale61.4711,975736,07242,564Jan 30 09:02 PM
Springhorn Jeremy P.DirectorJan 28Sale62.1980750,1906,005Jan 30 08:57 PM
Meek David D.DirectorJan 28Sale62.1972244,9032,508Jan 30 08:54 PM
Gut RobertChief Medical OfficerJan 28Sale62.1959637,06527,885Jan 29 06:02 PM
Gut RobertChief Medical OfficerJan 27Sale60.016,897413,88928,481Jan 29 06:02 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 27Sale65.5528,2891,854,280339,162Jan 29 11:24 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Option Exercise5.314,00021,24045,578Jan 17 09:39 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Sale68.974,000275,88041,578Jan 17 09:39 AM
Soteropoulos PaulaDirectorJan 07Sale72.183,000216,5405,352Jan 08 01:48 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Option Exercise7.537,33955,263374,991Dec 20 04:13 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Sale70.097,540528,510367,451Dec 20 04:13 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Option Exercise5.314,00021,24045,578Dec 17 04:09 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Sale74.594,000298,35641,578Dec 17 04:09 PM
Soteropoulos PaulaDirectorDec 13Option Exercise5.372,00010,74010,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 13Sale70.502,000141,0008,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 09Sale67.502,500168,7508,352Dec 09 06:30 PM
Soteropoulos PaulaDirectorDec 06Sale64.269,082583,60010,852Dec 09 06:30 PM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 20Sale53.748,000429,951367,652Nov 22 10:12 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Option Exercise5.314,00021,24045,578Nov 19 08:51 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Sale52.084,000208,31041,578Nov 19 08:51 AM
open in yahoo | open in reuters | open in google
affiliate | advertise | contact | privacy | help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.